Business Wire

Inmarsat Unveils the Communications Network of the Future

29.7.2021 12:47:00 EEST | Business Wire | Press release

Share

Today, Inmarsat unveiled plans for ORCHESTRA, the communications network of the future. In the largest ever transformation of its current world-class services, Inmarsat ORCHESTRA will bring together existing geosynchronous (GEO) satellites with low earth orbit satellites (LEO) and terrestrial 5G into an integrated, high-performance solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005443/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Inmarsat unveils ORCHESTRA, the communications network of the future (Graphic: Business Wire)

Whether for a ship in a crowded port, an aircraft preparing to land at LAX, or a defence force deployed in a remote location, ORCHESTRA is designed to meet evolving connectivity needs in the mobility market with a service unmatched by any competitor offering, planned or in existence.

“An orchestra brings different instruments together, each supporting the other and playing its role in the masterpiece. We’re building ORCHESTRA on the same concept,” said Rajeev Suri, CEO of Inmarsat. “By combining the distinct qualities of GEO, LEO and 5G into a single network, we will deliver a service that is far greater than the sum of its parts. Our customers will benefit from dramatically expanded high throughput services around the world. This is the future of connectivity and Inmarsat is perfectly positioned to bring it to the world with its proven technology expertise, right base of customers and partners, and financial strength.”

ORCHESTRA will open up a host of new and previously unattainable possibilities for industries across the world. New services include close-shore navigation for autonomous vessels, next-generation emergency safety services for maritime crews, secure and tactical private networks for governments and direct-to-cloud connections for airlines. New segments set to benefit from ORCHESTRA include energy rigs and drilling platforms, mid-market business aircraft, coastal vessels, smart passenger ships and urban air mobility.

ORCHESTRA is unique because it draws together the benefits of multiple technologies to create one cohesive solution. LEO, GEO and terrestrial networks have never been combined at scale before to create a unified connectivity service for mobility customers. The result is a ‘dynamic mesh network’ that will deliver high-performance connectivity everywhere. Bringing together the lowest average latency and fastest average speeds with unique resilience, ORCHESTRA will eliminate the industry-wide challenge of congested network ‘hot spots’.

Inmarsat’s existing GEO satellites – both GX and L-band - will continue to provide global coverage, high performance, security and resilience. Terrestrial 5G adds ultra-high capacity in busy ‘hot spots’, such as ports, airports, and sea canals. A small constellation of LEO satellites will layer additional high capacity over further high-demand areas such as oceanic flight corridors. As a result, the network will offer the highest capacity for mobility users worldwide, and at ‘hot spots’.

The network will benefit from ‘dynamic mesh’ technology, which allows individual customer terminals to direct traffic to and from other customer terminals. This means that a ship within reach of a 5G ground station can receive ample capacity for its own needs as well as route capacity onwards to other vessels beyond terrestrial reach. This effectively creates a mobile web of terminals that extend the network’s reach and improve its performance and resilience.

“ORCHESTRA ensures Inmarsat is well positioned to deliver long-term, profitable growth by delivering new services to existing customers, targeting near-adjacent market segments, and maintaining a strong competitive position,” said Suri. “We have a record of adopting the right technology at the right time. We plan to focus initially on delivering the ORCHESTRA terrestrial network, while preparing for a future LEO constellation in the range of 150-175 satellites. This is a highly cost-effective approach that leverages Inmarsat’s leading GEO satellite networks as part of ORCHESTRA’s unique multi-layer architecture.”

The new approach means that Inmarsat can easily boost capacity in high-density areas such as ports and airports, ensuring customer needs continue to be met well into the future with capacity scaled directly to match their requirements. The initial five-year (2021-2026) total investment for ORCHESTRA is expected to be in the order of $100m.

ENDS

About Inmarsat

Inmarsat is the world leader in global, mobile satellite communications. It owns and operates the world’s most diverse global portfolio of mobile telecommunications satellite networks, and holds a multi-layered, global spectrum portfolio, covering L-band, Ka-band and S-band, enabling unparalleled breadth and diversity in the solutions it provides. Inmarsat’s long-established global distribution network includes not only the world’s leading channel partners but also its own strong direct retail capabilities, enabling end to end customer service assurance.

The company has an unrivalled track record of operating the world’s most reliable global mobile satellite telecommunications networks, sustaining business and mission critical safety & operational applications for more than 40 years. It is also a major driving force behind technological innovation in mobile satellite communications, sustaining its leadership through a substantial investment and a powerful network of technology and manufacturing partners.

Inmarsat operates across a diversified portfolio of sectors with the financial resources to fund its business strategy and holds leading positions in the Maritime, Government, Aviation and Enterprise satcoms markets, operating consistently as a trusted, responsive and high-quality partner to its customers across the globe.

For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jonathan Sinnatt/ Matthew Knowles
Corporate Communications
Tel: +44 (0)20 7728 1518/1355
press@inmarsat.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye